Effects of antilipolytic drugs on cyclic 3',5'-AMP dependent protein kinase.
D000273:Adipose Tissue / Q000201:enzymology*; D000818:Animals; D002417:Cattle; D002738:Chloroquine / Q000494:pharmacology; D000242:Cyclic AMP; D004305:Dose-Response Relationship, Drug; D005439:Flufenamic Acid / Q000494:pharmacology; D066298:In Vitro Techniques; D007328:Insulin / Q000494:pharmacology; D050356:Lipid Metabolism; D008528:Mefenamic Acid / Q000494:pharmacology*; D009132:Muscles / Q000201:enzymology; D009539:Nicotinic Acids / Q000494:pharmacology; D009638:Norepinephrine; D010646:Phentolamine / Q000494:pharmacology; D010653:Phenylbutazone / Q000494:pharmacology*; D010770:Phosphotransferases / Q000037:antagonists & inhibitors*; D011433:Propranolol / Q000494:pharmacology; D011453:Prostaglandins / Q000494:pharmacology; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology; D013806:Theophylline / Q000494:pharmacology
D007328:Insulin; D009539:Nicotinic Acids; D011453:Prostaglandins; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D008528:Mefenamic Acid; D005439:Flufenamic Acid; D002738:Chloroquine; D011433:Propranolol; D013806:Theophylline; D000242:Cyclic AMP; D010770:Phosphotransferases; D011494:Protein Kinases; D010653:Phenylbutazone; D009638:Norepinephrine; D010646:Phentolamine